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Single-chain variable fragment (scFvs) antibodies are
small polypeptides (∼26 kD) containing the heavy (VH)
and light (VL) immunoglobulin domains of a parent anti-
body connected by a ﬂexible linker. In addition to being
frequently used in diagnostics and therapy for an increas-
ing number of human diseases, scFvs are important
tools for structural biology as crystallization chaperones.
Although scFvs can be expressed in many different
organisms, the expression level of an scFv strongly
depends on its particular amino acid sequence. We report
here a system allowing for easy and efﬁcient cloning of (i)
scFvs selected by phage display and (ii) individual heavy
and light chain sequences from hybridoma cDNA into
expression plasmids engineered for secretion of the re-
combinant fragment produced in Drosophila S2 cells. We
validated the method by producing ﬁve scFvs derived
from human and murine parent antibodies directed
against various antigens. The production yields varied
between 5 and 12 mg monomeric scFv per liter of super-
natant, indicating a relative independence on the individ-
ual sequences. The recombinant scFvs bound their
cognate antigen with high afﬁnity, comparable with the
parent antibodies. The suitability of the produced recom-
binant fragments for structural studies was demonstrated
by crystallization and structure determination of one of
the produced scFvs, derived from a broadly neutralizing
antibody against the major glycoprotein E2 of the hepa-
titis C virus. Structural comparison with the Protein
Data Bank revealed the typical spatial organization of VH
and VL domains, further validating the here-reported
expression system.
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Introduction
A single-chain variable fragment (scFv) is a portion of a
monoclonal antibody (MW 26 kD), in which the variable
immunoglobulin domains of the heavy (VH) and light (VL)
chains are connected with a ﬂexible linker into a single poly-
peptide chain (Bird et al., 1988; Huston et al., 1988). Thus,
an scFv contains the entire antigen-binding region, and hence
the speciﬁcity, of the parent antibody (Bird et al., 1988;
Huston et al., 1988; Sandhu, 1992; Holliger and Hudson,
2005). The two variable domains are tethered together in
either order (VH–VL or VL–VH), with a linker that is
usually 10–25 amino acids in length, spanning the 35–40 A ˚
distance from the C-terminus of one V domain to the
N-terminus of the other (Filpula et al., 1996; Weisser and
Hall, 2009). The length of this linker plays a crucial role for
the oligomeric state of the soluble puriﬁed scFv (Arndt
et al., 1998; Filpula et al., 1996), the most common linker
being a 15mer (Gly4Ser)3 (Huston et al., 1988; Weisser and
Hall, 2009).
Importantly, scFvs usually bind their cognate antigens
with afﬁnity similar to that of the parent antibody (Bird
et al., 1988; Huston et al., 1988, 1996; Skerra and Plu ¨ckthun,
1988; Weisser and Hall, 2009)–if the avidity effect of the
bivalency of the latter is taken into account. This is due to
the identical 3D arrangement of the variable domains. This
feature, combined with the small size of scFvs, has made
them attractive candidates for a wide range of applications,
including therapeutics, medical imaging and diagnostics
(Begent et al., 1996). scFvs and scFv-based antibody frag-
ments are currently in pre-clinical and clinical trials to treat
human diseases ranging from heart disease to melanoma, and
also for use in medical imaging (reviewed in Holliger and
Hudson, 2005). In addition, scFvs have shown promise in
drug delivery systems and for the targeting of gene therapy
vectors (Glasgow et al., 2009; Eisenstein, 2011).
The compact fold of scFvs, composed of two immuno-
globulin domains each consisting of nine strands forming
two tightly packed b-sheets stabilized by an intrachain disul-
ﬁde bond, provides additional protein surfaces that can help
to form a crystal lattice and thus promote crystallization of
macromolecules (Kovari et al., 1995; Grifﬁn and Lawson,
2011). Such an approach is particularly useful when dealing
with proteins that are difﬁcult to crystallize, such as heavily
glycosylated proteins, or multidomain proteins with relatively
ﬂexible interdomain connections. Moreover, the compactness
of scFvs makes them ideal candidates for structural studies
on antigen–antibody binding, such as the characterization
of the neutralization mechanism of certain monoclonal
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2009). These studies would be extremely difﬁcult to perform
using full-length bivalent antibody molecules, and are some-
times hindered by the ﬂexibility of the elbow angle between
variable and constant domains in Fab (fragment antigen-
binding) fragments.
Various expression systems for scFvs have been reported,
including Escherichia coli, yeast, fungi, plants, insect and
mammalian cells (Bird et al., 1988; Wu et al., 1993; Jost
et al., 1994; Ridder et al., 1995; Brocks et al., 1997);
reviewed in Verma et al. (1998) and Weisser and Hall
(2009). Numerous studies have been performed to evaluate
quantity and quality of scFvs produced in different expres-
sion systems. The advantages and drawbacks of the most fre-
quently used expression systems are summarized in Table I.
Importantly, in spite of numerous expression systems that
have been explored for scFv expression, the expected effort
required to produce large quantities of an scFv derived from
a particular parent antibody strongly depends on the individ-
ual amino acid sequence (Verma et al., 1998). Given that it
is important to consistently obtain large quantities of pure
scFv for structural analyses, as well as for diagnostic or
therapeutic applications, we decided to further explore the
use of the Drosophila Schneider 2 system for expression of
scFvs. This system has been previously used to produce
scFvs, but the reported expression levels varied by almost
two orders of magnitude (0.2–20 mg/l) (Mahiouz et al.,
1998; Reavy et al., 2000). High-yield expression of full-
length monoclonal antibodies and Fab-fragments in S2 cells
has also been reported (Johansson et al., 2007a; Backovic
et al., 2010). The Drosophila S2 expression system is rela-
tively easy to handle and is based upon logarithmically
growing healthy cell lines that have been transfected to
achieve stable expression of recombinant protein. This is in
contrast to the production in insect cells using a recombinant
baculovirus, which makes a lytic infection and induces con-
siderable stress to the infected cell. Baculoviral-aided expres-
sion can therefore lead to saturation of the endoplasmic
reticulum quality control system of the cell, especially when
overexpressing proteins with complex, disulﬁde-stabilized
folds. In such cases, baculovirus-induced cell lysis results in
dumping of protein that has not gone through the ER quality
control into the medium, resulting in a mixture of folded and
partially folded protein in the supernatant.
We undertook to establish an expression system for scFvs
that would allow easy cloning of the variable domains of
heavy and light chain and production of large amounts of
correctly processed and secreted scFvs using Drosophila S2
cells. We created a panel of scFvs from both human and
murine parent antibodies directed against various antigens. In
this paper we discuss in particular the production of ﬁve of
the recombinant proteins-scFv 3H5, derived from a murine
antibody to Npro of bovine viral diarrhea virus (BVDV);
scFv 8B9 and scFv 6A5, both derived from murine anti-
bodies to glycoprotein E2 of BVDV; and scFvs 1:7 and A8,
both derived from human antibodies to hepatitis C virus
glycoprotein E2 (Allander et al., 2000).
Materials and methods
Construction of pMT-based scFv expression vector
The pMT-scFv-Strep vector was constructed based on the
pT350 vector reported previously (Krey et al., 2010), con-
taining a Drosophila metallothionein (MT) promoter, a BiP
signal sequence and an enterokinase (EK) cleavage site
followed by a double Strep tag (NH2-DDDDKAGWSHPQ
FEKGGGSGGGSGGGSWSHPQFEK-COOH). First we
introduced NcoI and NotI sites by polymerase chain reaction
(PCR) using oligonucleotides 50-TTTTTTTTCCATGGCCCC
GAGCGAGAGGCCAAC AAAGG-30 and 50-AAAAAA
AAAGCGGCCGCAGACGATGACGATAAGGCCGGTTG-30
replacing BglII and BstBI sites used for cloning. In a subse-
quent PCR step KpnI and NheI sites were inserted using oli-
gonucleotides 50-GGAGGAGCTAGCAAAAAAGCGGCCG
CAGACGATGACG-30 and 50-TCCCGAGCCGCCGGTACC
TTTTTTCCATGGCCCCGAGCGAG-30. Finally, the com-
plete linker sequence GGS(GGGGS)2GGG was inserted by
PCR using oligonucleotides 50-CCACCCGATCCTCCTCC
TCCCGAGCCGCCGGTACCTTTTTTCCA-30 and 50-TGGT
GGTAG CGGAGGAGGAGCTAGCAAAAAAGCGGCCGC
AGACGATG-30.
Table I. Advantages and disadvantages of different expression systems for
scFvs
Expression system Advantages Disadvantages
Bacterial expression
(E.coli)
† Fast and easy
† Inexpensive
† Upscaling
feasible
† High yields
( 2 g/l) for
cytoplasmic
expression
† Endotoxin levels high
† Refolding necessary
for inclusion bodies
† Yields depend on
individual amino acid
sequence
† No glycosylation
possible
† No ER quality
control
Yeast expression
(Saccharomyces
cerevisiae,
Kluyveromyces lactis,
Pichia pastoris)
† No endotoxin
† Relatively
inexpensive
† High yields
† Glycosylation
possible
† Upscaling more
complicated than for
bacteria
† Need patent license
to make yeast glycans
suitable for
therapeutic
applications
Plants † No endotoxin
† Upscaling
feasible
† Glycosylation
possible
† High yields
† High technical
hurdles
† Need patent license
to make yeast glycans
suitable for
therapeutic
applications
Insect cells † No endotoxin
† Glycosylation
possible
† Upscaling
feasible
† ER quality control
insufﬁcient
(baculovirus)
† Unsuitability of insect
glycans for
therapeutic
applications
Mammalian cells † No endotoxin
† Glycosylation
possible
† Mammalian
glycosylation
type
† Moderate yields
† Upscaling difﬁcult
† Secretion problems of
certain antibody
sequences
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60Cloning of pMT-scFv-#-Strep constructs
The respective DNA sequences of the individual parent anti-
bodies have either been reported previously (1:7, A8;
Allander et al., 2000) or were obtained from sequencing of
the respective hybridoma cell line (8B9, 6A5, 3H5). The VH
and VL of the individual scFvs were inserted into the
pMT-scFv-Strep vector in two successive rounds of cloning.
AV L gene was ampliﬁed by PCR using either cDNA of
hybridoma cells (8B9, 6A5) or synthetic genes, codon
optimized for Drosophila melanogaster (3H5, 1:7, A8), as
template. The ampliﬁed segment was cloned into
pMT-scFv-Strep vector using NheI and NotI. Insertion of the
VL gene into the resulting pMT-scFv-#-VL-Strep constructs
was conﬁrmed by sequencing. The respective VH gene was
subsequently ampliﬁed by PCR using either cDNA of hybri-
doma cells (8B9, 6A5) or synthetic genes, codon optimized
for D.melanogaster (3H5, 1:7, A8), as template. The ampli-
ﬁed VH sequence was cloned into the newly created
VL-containing pMT-scFv-#-VL-Strep vector using NcoI and
KpnI. The resulting pMT-scFv-#-Strep constructs were
sequenced to conﬁrm insertion of both the VL and the VH.A
full list of oligonucleotides used for cloning of VH and VL
genes is included as Supplementary material (Table S1).
Transfection of the cells and expression of the scFv
Transfection of Drosophila S2 cells was done as described
before (Johansson et al., in press). Brieﬂy, we used Effectene
(Qiagen, Hilden, Germany) according to the manufacturer’s
recommendations, to transfect parental S2 cells with 2 mg
of the respective pMT-scFv-#-Strep plasmids. A second
plasmid, encoding puromycin acetyltransferase, was cotrans-
fected as dominant selectable marker. Stable scFv expressing
cell lines were selected by addition of 8 mg/ml Puromycin
(Invivogen, San Diego, USA) to the culture medium 72 h
after transfection. Adaptation of the cell lines to serum free
Insect Xpress media was performed stepwise as recom-
mended by Invitrogen.
Expression and puriﬁcation of scFvs
For large-scale production of scFvs the cells were cultured in
spinner ﬂasks and induced with 4 mM CdCl2 at a density of at
least 7   10
6 cells/ml. After 7–10 days at 288C cells were
pelleted and the scFv was puriﬁed by afﬁnity chromatography
from the supernatant using a StrepTactin Superﬂow column
(IBA, Goettingen, Germany) followed by size exclusion chro-
matography (SEC) using a Superdex200 column (GE
Healthcare, Uppsala, Sweden). Pure protein was quantiﬁed
using adsorption at UV280nm and concentrated to 10 mg/ml.
Refolding of dimeric scFvs
Dimeric scFvs were diluted to  100 mg/ml and dissociated
by overnight dialysis in dialysis buffer (0.3 M NaCl, 20 mM
Tris pH 8.0) containing 8 M urea. Subsequently, the dimeric
fragments were refolded by a stepwise dialysis overnight at
48C against 1 l dialysis buffer containing decreasing concen-
trations of urea (8, 6, 4, 2, 1, 0.5 and 0 M). The buffers con-
taining 1 and 0.5 M urea were supplemented with 0.4 M
L-arginine. The oligomerization state of the refolded scFvs
was analyzed by SEC using a SuperdexTM 200 column.
SEC analysis of antigen-scFv complexes
Twenty micrograms of scFv (ﬁnal concentration 0.2 mg/ml)
and 20–35 mg (ﬁnal concentration 0.2–0.35 mg/ml) of
antigen (depending on its molecular weight), were incubated
as isolated proteins as well as in complex for 24 h at 48C fol-
lowed by analysis on a SuperdexTM 200 5/150GL column
(column volume 3 ml, GE Healthcare).
Crystallization of scFv 1:7, data collection, structure
determination and reﬁnement
Crystals of scFv 1:7 were grown at 293 K using the sitting-
drop vapor-diffusion method. Crystallization was performed
using a Mosquito robot (TTP LabTech Ltd, Royston, UK) in
a drop containing 800 nl protein (7 mg/ml in 10 mM TRIS
pH 8.0, 150 mM NaCl) mixed with 800 nl reservoir solution
containing 100 mM TRIS pH 8.5, 1550 mM (NH4)2SO4 and
200 mM Li2SO4. Diffraction quality crystals appeared after 1
week and were ﬂash frozen in mother liquor containing
25% (v/v) glycerol. Diffraction data were collected at the
Proxima1 beam line of Synchrotron Soleil and processed
with XDS (Kabsch, 2010). Scaling and reduction of the data
were performed using Pointless (Evans, 2005) and programs
from the CCP4 suite (Collaborative Computational Project,
1994). The structure was determined by molecular replace-
ment using Phaser (McCoy et al., 2007), an scFv derived
from a human antibody served as model (PDB 3FKU; Sui
et al., 2009). Model building was performed using Coot
(Emsley et al., 2010) and reﬁnement was done using
AutoBuster (Bricogne et al., 2010). Figure 4 was prepared
with Pymol (http://www.pymol.org). The atomic coordinates
of the structural model and the corresponding structure
factors were deposited in the Protein Data Bank with ID
3U6R.
Results and discussion
Design of the expression plasmid
The pMT-scFv-Strep vector was designed based upon an
expression plasmid previously described (Krey et al., 2010)
that contained an inducible Drosophila MT promoter, fol-
lowed by a Drosophila BiP signal sequence, which leads to
efﬁcient translocation of the protein into the ER. At the
C-terminus, this plasmid contains a double Strep-tag for efﬁ-
cient afﬁnity puriﬁcation and an EK cleavage site upstream
of the double Strep-tag to allow for its speciﬁc removal for
therapeutic applications or structural studies.
The pMT-scFv-Strep was designed to contain the VH and
VL of a parent antibody in this order joined by a linker se-
quence (Fig. 1) that is meant to span the 35–40 A ˚ between
the C-terminus of VH and the N-terminus of VL. The major
requirement for this linker is sufﬁcient ﬂexibility, a rationale
that is followed in the most commonly used linker sequences
(Huston et al., 1991). Linker sequences are typically 10–25
amino acids, shorter linker sequences have been shown to
favor the formation of dimers or higher multimers (Huston
et al., 1988; Arndt et al., 1998; Filpula et al., 1996; Weisser
and Hall, 2009). To reduce the probability of oligomer for-
mation, a 16-residue GGGGS-linker was designed ﬂanked by
two restriction sites coding for residues that provide a high
degree of ﬂexibility, adding up to a ﬁnal linker length of 20
residues. We designed the vector to be compatible (50 and 30
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61restriction sites NcoI and NotI) to the pHEN2 plasmid fre-
quently used for phage display selection of high-afﬁnity anti-
bodies (Grifﬁths et al., 1994) allowing for efﬁcient transfer
of selected antibodies into the pMT-scFv-Strep vector. In
parallel, the linker sequence is framed by cloning sites for
directional cloning of the VH and VL facilitating easy
cloning of scFv fragments from hybridoma cDNA. The
design of this vector permitted efﬁcient and rapid two-step
cloning of all VH and VL scFv genes as described in the
Materials and methods section, generating the expression
plasmids pMT-scFv-3H5-Strep, pMT-scFv-6A5-Strep,
pMT-scFv-8B9-Strep, pMT-scFv-1:7-Strep and pMT-scFv-
A8-Strep, respectively.
Expression of scFvs in Drosophila S2 cells
In order to generate stable S2 cell lines expressing the
recombinant scFvs, S2 cells were transfected with the
respective pMT-scFv-#-Strep plasmid together with a
dominant-selectable marker (an expression plasmid encoding
Puromycin-Acetyltransferase; Iwaki et al., 2003). After selec-
tion, cells were adapted to serum-free Insect Xpress medium
(Lonza, Basel, Switzerland), ampliﬁed, and protein produc-
tion was induced by the addition of 4 mM CdCl2 as
described in the Materials and methods section. We puriﬁed
the secreted scFvs to homogeneity from the supernatant by
afﬁnity chromatography, with yields varying between 5 and
12 mg/l supernatant. Subsequently, we subjected the eluate
to SEC separating monomeric and dimeric scFv species
(Fig. 2A–E). All ﬁve scFvs from human and mouse origin
expressed a majority of monomeric scFv, as judged by SEC
followed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS–PAGE) analysis under non-reducing con-
ditions and Coomassie blue staining (Fig. 2F). In a typical
Fig. 2. Puriﬁcation of human and murine scFvs. ScFvs 6A5 (A), 3H5 (B), 8B9 (C), 1:7 (D) and A8 (E) were afﬁnity puriﬁed and subsequently SEC was
performed using a Superdex 200 column. Chromatograms show absorption at 280 nm (black) and 254 nm (light grey) and reveal for the majority of the scFvs a
major peak corresponding to a monomeric scFv (26 kD). In addition, particularly for scFv 8B9 (C), but less pronounced also for scFvs 6A5, 3H5 and 1:7
(A, B, D) a second peak was observed, which corresponds to a dimeric scFv (or diabody). For scFv 8B9 and scFv 6A5 (A, C) a minor peak was detected
corresponding to oligomeric scFv. (F) SDS–PAGE analysis of SEC elution fractions of scFv 1:7 under non-reducing conditions conﬁrms the diabodies to be
indeed non-covalent dimers. Fractions corresponding to diabodies of scFvs 8B9 and 1:7 were pooled separately, refolded as described in the Materials and
methods section and analyzed again by SEC. The SEC proﬁles of refolded scFvs 8B9 (G) and 1:7 (H) clearly demonstrate a shift of the elution peak of the
diabodies toward a monomeric scFv indicating an efﬁcient and successful refolding.
Fig. 1. Schematic representation of the pMT-scFv-Strep expression vector.
Cloning sites for the variable region of the heavy chain (VH) and the
variable region of the light chain (VL) are marked as well as the linker
sequence GT(GGSGG)3GAS including two restriction sites allowing for the
directional cloning of (VH) and (VL), coding for the bold, underlined
residues. The MT promoter and the BiP signal sequence are also marked. In
addition, the vector contains an EK cleavage site allowing removal of the
double Strep-tag in frame directly downstream of the VL-coding sequence.
A.A.Gilmartin et al.
62SEC proﬁle, the majority of the protein elutes at a volume
corresponding to a monomer. However, depending on the in-
dividual sequence, minor peaks corresponding to dimeric
and higher oligomeric scFvs could be observed (Fig. 2A–D).
Refolding of dimeric scFvs into monomers
The linker between the two variable domains allows the two
variable regions to form the authentic heterodimer; however,
it also opens up the possibility that the VH from one scFv
molecule may associate with the VL from another molecule,
resulting in a linear, antiparallel dimeric molecule or even
forming higher oligomers (Holliger et al., 1993). Dimeric
scFvs, also known as diabodies, have therapeutic applications
of their own. The extreme ﬂexibility in the Fv angle of these
oligomeric forms (Holliger and Hudson, 2005) is, however,
undesirable for structural studies.
Several studies have investigated the use of different
refolding procedures to scFvs (reviewed in Sinacola and
Robinson, 2002). To show that the dimeric protein produced
in S2 cells represents diabodies rather than aggregated or
misfolded protein, we pooled the dimer-containing fractions
of those scFvs exhibiting an elution pattern suggestive of
dimeric protein and applied a stepwise dialysis refolding
approach adapted from (Sinacola and Robinson, 2002).
Dimeric scFv at a concentration of 20–50 mg/ml was dia-
lyzed against 8 M urea in the absence of reducing agents to
dissociate oligomers. The urea concentration was then slowly
lowered to 0 to favor the formation of monomers over
dimers or multimers; L-arginine was added at the end of the
process, at the lowest urea concentrations, to promote refold-
ing and discourage the formation of aggregates (Chen et al.,
2009).
SEC analysis of the refolded scFv revealed that dimeric
scFvs 8B9 and 1:7 were entirely refolded into monomers
(Fig. 2G and H) in the absence of any reducing agents. This
indicates that the original dimeric species already contained
the correct disulﬁde connectivity in both heavy and light
chains, likely representing diabodies.
ScFvs interact with their cognate antigen
The parent antibodies of scFvs 8B9, 6A5 and A8 each bind
their cognate antigen BVDV E2 and HCV E2, respectively,
with high afﬁnity as suggested by the stability of all three
antibody–antigen complexes in SEC (data not shown). To
demonstrate that the afﬁnity of the monomeric scFvs to their
cognate antigen was similar to that of the full-length anti-
body we used SEC to assess the ability of the scFvs to inter-
act with its cognate antigen. Each scFv and its respective
cognate antigen were mixed and subsequently analyzed by
SEC. All three complexes of scFvs with their cognate
antigen were eluted considerably earlier than the respective
individual proteins (Fig. 3), indicating a stable complex for-
mation, as observed for the parent antibodies. This was also
observed for the scFv 8B9 after being subjected to the step-
wise dialysis refolding procedure (data not shown), indicating
Fig. 3. Functional characterization of recombinant scFvs. Complex formation between scFvs 8B9 (A), 6A5 (B) and A8 (C) and their respective cognate
antigen was analyzed by SEC analysis using a Superdex 200 5/150 column (CV 3 ml). The scFv, the respective antigen and a mixture of the two were loaded
to the column (in three different runs) (scFv 26 kD, HCV E2 50 kD, BVDV E2 monomer 50 kD, BVDV E2 dimer 100 kD, complexes with antigen
monomer 80 kD, complex with antigen dimer 160 kD). The peak corresponding to the free scFv in the chromatogram of the scFv-antigen complex for
scFv 8B9 (A) is likely due to a molar excess of scFv used in this experiment.
Table II. Details and statistics of data collection, processing and reﬁnement
for scFv 1:7 crystals
1:7 scFv
Data collection
Space group C2221
Cell dimensions
a, b, c (A ˚) 105.49, 105.74, 105.60
a, b, g (8) 90.0, 90.0, 90.0
Resolution (A ˚) 43.11–2.67 (2.81–2.67)
Rmerge 0.084 (0.459)
I/s I 11.5 (1.9)
Completeness (%) 92.5 (54.1)
Redundancy 3.5 (2.4)
Reﬁnement
No. reﬂections 15793
Rwork/Rfree 0.193/0.232
No. atoms
Protein 3604
B-factors
Protein 50.58
R.m.s. deviations
Bond lengths (A ˚) 0.01
Bond angles (8) 1.19
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63that the monomeric scFv resulting from the refolding proced-
ure also displays an antigen-binding capacity similar to the
parent antibody.
Crystal structure of scFv 1:7
One of the potential applications of a recombinant scFv is
the use in structural studies to facilitate crystallization of
interesting macromolecules that would not crystallize
otherwise. One example of such a molecule is the major
glycoprotein E2 of the Hepatitis C virus (HCV), the crystal
structure of which has still not been reported despite being
the focus of intense research efforts worldwide. One possible
strategy to promote crystallization of this multidomain,
heavily glycosylated envelope protein is cocrystallization in
complex with scFvs. To demonstrate the suitability of scFvs
produced in the reported S2 cell expression system for
Fig. 4. Crystal structure of scFv 1:7. The crystal structure of scFv 1:7 (A) viewed from the side (upper panel) and from the top (lower panel). Framework
regions are colored in dark blue (HC) or light blue (LC) and the CDRs according to the immunogenetics (IMGT) nomenclature are colored in yellow (CDR1),
green (CDR2) and red (CDR3). The side chains of the residues in the CDRs are shown as lines. (B) The 1:7 amino acid sequence was aligned with the closest
homologous germline sequence suggested by IMGT V-QUEST and junction analysis (Lefranc et al., 2009). Positions of somatic mutations during antibody
maturation are shaded, bars indicate the positions of the CDRs according to the IMGT nomenclature. (C) Mapping of the somatic mutations (brown) on the
molecular surface of scFv 1:7 from the side (upper panel) and from the top (lower panel).
A.A.Gilmartin et al.
64structural studies, we determined the crystal structure of the
scFv 1:7, which is derived from a broadly neutralizing
anti-HCV E2 antibody previously described (Allander et al.,
2000; Johansson et al., 2007b). Diffraction quality crystals of
the unliganded scFv, belonging to space group C2221, could
be grown within 1 week. These crystals diffracted to 2.7 A ˚
on a synchrotron source. We determined the crystal structure
of the scFv using the molecular replacement method; details
and statistics of the data collection, processing and reﬁne-
ment are given in Table II.
The scFv 1:7 displays the standard compact fold of two
heterodimerizing immunoglobulin domains, VH and VL,e a c h
containing nine b-strands tightly packed in two b-sheets
(Fig. 4A). The dimer interface between VH and VL buries
558 A ˚ 2 of solvent accessible surface, which is similar to
the buried surface area computed for the variable region
interface of other scFvs (e.g. PDB 1qok, 2ghw) or Fab mole-
cules (e.g. PDB 2xqy, 3n9g) of human and murine origin. A
structural comparison to the database using the DALI-server
(Holm and Rosenstro ¨m, 2010) followed by superposition
with the four closest structural neighbors (data not shown)
revealed no distortion between VH and VL. Taken together,
this set of evidence strongly suggests a 3D arrangement of
the scFv 1:7 that is identical to the variable region of the
parent antibody and thus further validates the expression
system presented in this study.
Antibody diversity is generated by the combinatorial asso-
ciation of V, D and J segments, which in addition becomes
further diversiﬁed at the actual junctions (VL–JL, VH–D
and D–JH) due to imprecise joining and addition of ‘N
region’ nucleotides. Somatic mutation, possibly driven by
antigenic selection, contributes further to antibody diversity
and leads to increased afﬁnity and speciﬁcity as antibody
maturation occurs (Tonegawa, 1983; French et al., 1989).
The closest homologous germline genes for the 1:7 antibody
suggested by immunogenetics (IMGT) V-QUEST and junc-
tion analysis (Lefranc et al., 2009) are IGHV1-69*01 F,
IGHJ4*02 F and IGHD2-2*01 F in the heavy chain and
IGKV3-11*01 F and IGKJ4*01 F in the light chain. The
same heavy chain V gene (IGHV1-69*01 F) was found in an
exceptional high frequency in anti-HCV-E2 antibodies
(Allander et al., 2000; Chan et al., 2001), suggesting a prefer-
ential usage of the same V gene in the speciﬁc immune re-
sponse to the HCV E2 glycoprotein. Antibodies derived from
IGHV1-69*01 F have been reported to undergo somatic
mutations during antigenic selection, with high frequency
located in or close to the complementarity determining
region (CDR) regions, indicating a positive selection for
antigen binding (Chan et al., 2001). We aligned the 1:7 VH
and VL amino acid sequence to the respective germline
sequences (Fig. 4B) and identiﬁed somatic mutations
acquired during antibody maturation. Subsequently, we
mapped those mutations on the surface of the scFv structure
(Fig. 4C). Mutations at the very N-terminus were disre-
garded, since they are very often due to the primer sequences
that have been used to isolate the antibody cDNA. We found
3 mutations in the light chain and 20 mutations in the heavy
chain, the majority of which clusters in or around the H1 and
H2 loop, while only 2 somatic mutations are found in the
long H3 loop. In the light chain two mutations are located on
the L1 loop and one in the L3 loop. These data suggest a
binding mode of this broadly neutralizing antibody to its
cognate antigen that is predominantly mediated by H1, H2
and H3 loops and supported by the L1 loop.
The fact that the crystal structure of the scFv 1:7 could be
obtained relatively easily, demonstrates that the scFvs pro-
duced in our expression system are applicable for the use in
structural studies. We expressed ﬁve different scFvs derived
from human and murine origin, including codon optimized
as well as hybridoma-derived DNA sequences and for all
ﬁve we obtained expression levels between 5 and 12 mg/l
supernatant. This suggests that the strong sequence depend-
ence that has been described for other expression systems
like E.coli and mammalian cells (Jost et al., 1994; Verma
et al., 1998; Weisser and Hall, 2009) is not observed in the
S2 cell expression system described here. We conclude that
our system is a very powerful tool, particularly for those anti-
bodies that remain–for yet unknown reasons–difﬁcult to
obtain in large-enough yields with other expression systems.
Supplementary data
Supplementary data are available at PEDS online.
Acknowledgements
We thank Patrick Weber of the PF6 for help with the crystallogenesis and
Andrew Thompson from the beamline PROXIMA 1 at the synchrotron
Soleil for help with data collection. We also thank Scott A.Jeffers for excel-
lent advice during protein puriﬁcation and Joseph J.Cockburn and Scott
A.Jeffers for helpful discussions.
Conﬂict of interest
The human antibodies A8 and 1:7 are protected in patents
owned by Molecules of Man AB, a spinoff company based
on discoveries made at Karolinska Institutet, Sweden.
M.A.A.P. has a ﬁnancial interest in the company as
shareholder.
Funding
A.A.G. beneﬁted from a Fulbright-Hays fellowship. This
work was supported by the ANRS and the ANR grant
ANR-2010-BLAN-1211 01 to F.A.R., in addition to the re-
current Institut Pasteur and CNRS support to F.A.R.; the
Swedish Foundation for Strategic Research (Cell Factory and
Infection &Vaccines programs), the Swedish Cancer Society
and the Swedish Research Council to M.A.A.P. Funding to
pay the Open Access publication charges for this article was
provided by the Institut Pasteur.
References
Allander,T., Drakenberg,K., Beyene,A., Rosa,D., Abrignani,S.,
Houghton,M., Widell,A., Grillner,L. and Persson,M.A. (2000) J Gen
Virol, 81, 2451–2459.
Arndt,K.M., Mu ¨ller,K.M. and Plu ¨ckthun,A. (1998) Biochemistry, 37,
12918–12926.
Backovic,M., Johansson,D.X., Klupp,B.G., Mettenleiter,T.C.,
Persson,M.A.A. and Rey,F.A. (2010) Protein Eng Des Sel, 23, 169–174.
Begent,R.H., Verhaar,M.J., Chester,K.A., et al. (1996) Nat Med, 2,
979–984.
Bird,R.E., Hardman,K.D., Jacobson,J.W., et al. (1988) Science, 242,
423–426.
Bricogne,G., Blanc,E., Brandl,M., et al. (2010) Cambridge, UK: Global
Phasing Ltd.
High-level scFv expression in Drosophila S2 cells
65Brocks,B., Rode,H.J., Klein,M., Gerlach,E., Du ¨bel,S., Little,M.,
Pﬁzenmaier,K. and Moosmayer,D. (1997) Immunotechnology, 3,
173–184.
Chan,C.H., Hadlock,K.G., Foung,S.K. and Levy,S. (2001) Blood, 97,
1023–1026.
Chen,J., Liu,Y., Li,X., Wang,Y., Ding,H., Ma,G. and Su,Z. (2009) Protein
expression and puriﬁcation, 66, 82–90.
Collaborative Computational Project. (1994) Acta Crystallogr D Biol
Crystallogr, 50, 760–763.
Eisenstein,M. (2011) Nat Biotechnol, 29, 107–109.
Emsley,P., Lohkamp,B., Scott,W.G. and Cowtan,K. (2010) Acta Crystallogr
D Biol Crystallogr, 66, 486–501.
Evans,P. (2005) Acta Crystallogr D Biol Crystallogr, 62, 72–82.
Filpula,D., McGuire,J. and Whitlow,M. (1996) In McCafferty,J.,
Hoogenboom,H. and Chiswell,D. (eds), Antibody engineering: a practical
approach. Oxford: Oxford University Press, pp. 253–268.
French,D.L., Laskov,R. and Scharff,M.D. (1989) Science, 244, 1152–1157.
Glasgow,J.N., Mikheeva,G., Krasnykh,V. and Curiel,D.T. (2009) PLoS ONE,
4, e8355.
Grifﬁn,L. and Lawson,A. (2011) Clin Exp Immunol, 165, 285–291.
Grifﬁths,A.D., Williams,S.C., Hartley,O., et al. (1994) EMBO J, 13,
3245–3260.
Holliger,P. and Hudson,P.J. (2005) Nat Biotechnol, 23, 1126–1136.
Holliger,P., Prospero,T. and Winter,G. (1993) Proc Natl Acad Sci USA, 90,
6444–6448.
Holm,L. and Rosenstro ¨m,P. (2010) Nucleic Acids Res, 38, W545–W549.
Huston,J.S., Levinson,D., Mudgett-Hunter,M., et al. (1988) Proc Natl Acad
Sci USA, 85, 5879–5883.
Huston,J.S., Margolies,M.N. and Haber,E. (1996) Adv Protein Chem, 49,
329–450.
Huston,J.S., Mudgett-Hunter,M., Tai,M.S., McCartney,J., Warren,F.,
Haber,E. and Oppermann,H. (1991) Methods Enzymol, 203, 46–88.
Hwang,W.C., Lin,Y., Santelli,E., Sui,J., Jaroszewski,L., Stec,B., Farzan,M.,
Marasco,W.A. and Liddington,R.C. (2006) J Biol Chem, 281,
34610–34616.
Iwaki,T., Figuera,M., Ploplis,V.A. and Castellino,F.J. (2003) Biotechniques,
35, 482–484, 486.
Johansson,D.X., Drakenberg,K., Hopmann,K.H., Schmidt,A., Yari,F.,
Hinkula,J. and Persson,M.A.A. (2007a) J Immunol Methods, 318, 37–46.
Johansson,D.X., Krey,T. and Andersson,O. (in press) In Chames,P. (ed),
Antibody engineering: methods and protocols. Totowa, N.J.: Humana
Press.
Johansson,D.X., Voisset,C., Tarr,A.W., Aung,M., Ball,J.K., Dubuisson,J. and
Persson,M.A.A. (2007b) Proc Natl Acad Sci USA, 104, 16269–16274.
Jost,C.R., Kurucz,I., Jacobus,C.M., Titus,J.A., George,A.J. and Segal,D.M.
(1994) J Biol Chem, 269, 26267–26273.
Kabsch,W. (2010) Acta Crystallogr D Biol Crystallogr, 66, 125–132.
Kovari,L.C., Momany,C. and Rossmann,M.G. (1995) Structure, 3,
1291–1293.
Krey,T., d’Alayer,J., Kikuti,C.M., et al. (2010) PLoS Pathog, 6, e1000762.
Lefranc,M.-P., Giudicelli,V., Ginestoux,C., et al. (2009) Nucleic Acids Res,
37, D1006–D1012.
Mahiouz,D.L., Aichinger,G., Haskard,D.O. and George,A.J. (1998) J
Immunol Methods, 212, 149–160.
McCoy,A.J., Grosse-Kunstleve,R.W., Adams,P.D., Winn,M.D., Storoni,L.C.
and Read,R.J. (2007) J Appl Crystallogr, 40, 658–674.
Reavy,B., Ziegler,A., Diplexcito,J., Macintosh,S.M., Torrance,L. and
Mayo,M. (2000) Protein Expr Purif, 18, 221–228.
Ridder,R., Schmitz,R., Legay,F. and Gram,H. (1995) Biotechnology (NY),
13, 255–260.
Sandhu,J.S. (1992) Crit Rev Biotechnol, 12, 437–462.
Sinacola,J.R. and Robinson,A.S. (2002) Protein Expr Purif, 26, 301–308.
Skerra,A. and Plu ¨ckthun,A. (1988) Science, 240, 1038–1041.
Sui,J., Hwang,W.C., Perez,S., et al. (2009) Nature Struct Mol Biol, 16,
265–273.
Tonegawa,S. (1983) Nature, 302, 575–581.
Verma,R., Boleti,E. and George,A.J. (1998) J Immunol Methods, 216,
165–181.
Weisser,N.E. and Hall,J.C. (2009) Biotechnol Adv, 27, 502–520.
Wu,X.C., Ng,S.C., Near,R.I. and Wong,S.L. (1993) Biotechnology (NY), 11,
71–76.
A.A.Gilmartin et al.
66